Affimed Therapeutics, the developer of TandAb antibodies, has welcomed Jens-Peter Marschner as Chief Medical Officer.
Marschner has joined the firm from Merck KGaA. He has 18 years of experience in clinical development with a focus on biological compounds.
He led the clinical development team of cetuximab (Erbitux), a monoclonal antibody to treat colorectal cancer, which was launched in 2004.
During his career he has also been responsible for the early and late stage development of cancer immune therapies. As VP Global Medical Affairs at Merck KgaA, Marschner gained broad experience in market-related medical and scientific affairs, primarily in the field of oncology.
Marschner initially trained and worked as a medical doctor. After finishing the clinical work at a general hospital (internal medicine) he worked at the University Hospital Frankfurt/Main where he became a board certified Clinical Pharmacologist. He started his pharmaceutical career in 1995 at Boehringer Mannheim, which is now part of Roche.
After a short tenure at Bayer he joined Merck KGaA in 1999. Along with his responsibility for the development of several biological compounds he managed different global teams in Clinical Development and Medical Affairs.
